Hutchmed, AZ file Orpathys for lung cancer on ESMO data
Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.
Inovio stock rises 2.5-fold on plasmid DNA drug approval
Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.
Aspen, Bambusa close IPOs as Corxel takes SPAC route
Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Sanofi eyeing pipeline deals ahead of Dupixent patent loss
Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.
AZ seeking $1.5bn in annual savings by end-2029
AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
ISMAI 2026: Florence to host international symposium on the ...
On 3 and 4 December, in the CTO Auditorium of Careggi University Hospital, clinicians, scientists and international experts will discuss clinical judgement, patient safety and professional acco
11th Liquid Biopsy for Precision Oncology Summit West Coast
Your industry-leading, flagship West Coast meeting uniting the global liquid biopsy community
31st Edition Strategic Project & Portfolio Management for Ph...
The Marcus Evans 31st Edition Strategic Project & Portfolio Management for Pharma conference, for European pharmaceutical PMO and portfolio leaders.
Women in AI - an evening of practical AI learning
Women in AI returns November 10 in London, UK. Join women from across healthcare for an evening of practical AI learning.
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne